New Report Highlights Value of Treatments to Patients
A recent report by the Alliance for Patient Access (AfPA) titled “At What Price? Medication Value, Patient Care & the…
Browsing: Drug Pricing: Policy Activity
GOA Finds Rebates Do Not Lower Consumer Costs
A recent report by the Government Accountability Office found that despite the substantial rebates private plans received for Medicare Part…
MDPC sends letter to MA Legislature on Use of QALYs
On September 19, 2023, the Movement Disorders Policy Coalition (MDPC) sent a letter to Chairwoman Friedman and Chairman Lawn of…
Aimed Alliance Comments on CMS’s 340B Proposed Rule
On September 11, 2023, Aimed Alliance sent a letter to Centers for Medicare and Medicaid Services (CMS) commenting on CMS’s…
Report Suggests Fair Access Criteria as Effective Tool to Encourage Increased Drug Access
On January 17, 2023, the Institute for Clinical and Economic Review (ICER) published its second annual “Barriers to Fair Access”…
Aimed Alliance Comments on Build Back Better and Future Healthcare Reform
On November 26, 2021, Aimed Alliance sent a letter to U.S. Senators Carper, Coons, Cortez, Masto, Menendez, Murray, Sinema, Schumer and Wyden…
CMS Delays Two Years Policy Drug Makers Say Undermines Copay Coupons
On December 21, 2020, the Centers for Medicare and Medicaid Services (CMS) finalized a rule to alter the method by…
New Study Shows Out-of-Pocket Spending Decreased Significantly After States Cap the Copay
According to a new study in the New England Journal of Medicine (NEJM), three states have helped their residents save…
House to Vote on Bill to Expand the ACA But It Also Includes Drug Price Controls
Today, the House is set to vote on H.R. 1425, “Patient Protection and Affordable Care Enhancement Act.” The bill contains…
Aimed Alliance Comments on the Lower Health Care Costs Now Act of 2019
On November 8, 2019, Aimed Alliance submitted a comment to congressional leaders regarding the Lower Health Care Costs Now Act…